Slower CKD Progression with RASIs versus CCBs

Full access

Patients taking renin-angiotensin system inhibitors (RASIs) have slower progression of kidney disease than those taking calcium channel blockers (CCBs), according to a “real-world” study in the American Journal of Kidney Diseases.

With the use of 2007−2017 data from the Swedish Renal Registry, researchers identified two groups: 2458 new users of RASIs and 2345 patients starting treatment with CCBs. At a median follow-up of 4.1 years, rates of KRT initiation, death from any cause, and major adverse cardiovascular events (MACEs) were compared between the two treatment groups. Patients with stage 3 CKD taking the same medications were studied as

Patients taking renin-angiotensin system inhibitors (RASIs) have slower progression of kidney disease than those taking calcium channel blockers (CCBs), according to a “real-world” study in the American Journal of Kidney Diseases.

With the use of 2007−2017 data from the Swedish Renal Registry, researchers identified two groups: 2458 new users of RASIs and 2345 patients starting treatment with CCBs. At a median follow-up of 4.1 years, rates of KRT initiation, death from any cause, and major adverse cardiovascular events (MACEs) were compared between the two treatment groups. Patients with stage 3 CKD taking the same medications were studied as positive controls.

“These findings suggest that RASi initiation might slow the progression of kidney disease compared with CCB in patients with advanced CKD, and offer similar cardiovascular protection,” the investigators conclude [Fu EL, et al. Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: A nationwide observational cohort study. Am J Kidney Dis, published online ahead of print November 24, 2020. doi: 10.1053/j.ajkd.2020.10.006; https://www.ajkd.org/article/S0272-6386(20)31121-5/fulltext].

Save